A natural microorganism and plant-derived composite dual adjuvant capable of efficiently inducing humoral and cellular immunity, and its preparation method and application
Through the combined double adjuvant of monophosphoryl lipid A and Ophiopogonis saponin, the deficiency of existing vaccine adjuvant in immunogenicity and safety is solved, and the efficient induction of multiple immune responses is achieved, which is suitable for a variety of vaccines and The population has improved the immune effect and safety of the vaccine.
Patent Information
- Application Number
- CN202210138429.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-02-15
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-02-15
AI Technical Summary
Existing vaccine adjuvants have shortcomings in improving immunogenicity and safety, are not targeted, and their immune mechanism is unclear, resulting in limited application scope, especially natural plants or microbial adjuvants that are difficult to induce at the same time. Various types of immune responses, both with safety and low cost requirements.
Using a composite double adjuvant of monophosphoryl lipid A and Ophiopogonis saponin, a natural microbial and plant-derived complex adjuvant that can efficiently induce humoral and cellular immunity is formed for vaccine adjuvant. agents can synergistically enhance immune responses and balance Th1 and Th2 types of reactions.
It has achieved efficient induction of humoral and cellular immune responses, improved the immunogenicity and safety of the vaccine, and is suitable for a variety of vaccines and populations, especially individuals with low immune function, reduced the number of vaccination times and adverse reactions, and improved immune memory. and tolerate.
Smart Images

Figure CN114366810B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of immunology, and in particular to a natural microorganism and plant-derived composite double adjuvant capable of efficiently inducing humoral and cellular immunity, and application thereof. Background Art
[0002] Vaccines are autoimmune preparations for preventing infectious diseases made by artificially attenuating, inactivating or genetically modifying pathogenic microorganisms (such as bacteria, rickettsia, viruses, etc.) and their metabolites. If there are only antigen components in the vaccine composition, the immunogenicity is often not strong enough, and injection into the human body may not cause sufficient immune response, which is not enough to resist the invasion of the corresponding pathogens. Therefore, when using vaccines, they are often injected together with vaccine adjuvants. Vaccine adjuvants are a class of substances that can non-specifically change or enhance the body's specific immune response to antigens and play an auxiliary role. They can induce the body to produce long-term and efficient specific immune responses, improve the body's protective ability, and at the same time reduce the amount of vaccine antigens and reduce the production cost of vaccines. In the process of vaccine development, in order to prepare safe and effective vaccines, the use of adjuvants must be considered. The compatibility of adjuvants and vaccine components enables the two to form a stable, safe and immunogenic vaccine complex. Therefore, research on adjuvants used in vaccines has always been an important part of the vaccine research process. As a non-specific immune enhancer, adjuvants play a vital role in inducing effective immune responses after vaccination.
[0003] Adjuvant refers to a substance that is used simultaneously with or in advance of an antigen and can effectively enhance the body's immune response to the antigen or change the type of immune response, but it itself is not immunogenic and cannot act alone to cause an immune response. Currently, commonly used adjuvants include aluminum hydroxide, liposomes, Freund's adjuvant, mucosal immune adjuvants, CpG sequences, saponins, cytokines, nanoparticles, and other natural microbial and plant-derived adjuvants, all of which can effectively enhance the immunogenicity of antigens. However, the only human vaccine adjuvant currently available on the market and approved by the US FDA is aluminum hydroxide adjuvant. There are a few vaccine adjuvants approved and marketed by the European Union, such as MF59, recombinant cholera toxin B subunit, and AS series (AS04, 03, 01). Although the research on adjuvants is extensive and in-depth, few of them can be applied. The main reasons are as follows: First, the safety of adjuvants still needs to be further improved; second, the targeting of adjuvants is still not strong, and the effect of enhancing the immunogenicity of vaccines is still not ideal, which restricts the scope of application of adjuvants; third, the immune mechanism of most adjuvants is still unclear. Although many adjuvants have been proven to have good immune enhancement effects, there are still many different opinions on their mechanism of action internationally; fourth, the selection of adjuvant immunization pathways, dosage setting, and the selection of adjuvant types are also problems that need to be faced in their development. However, most of the above-mentioned vaccine adjuvants act on the activity of T cells and antigen presenting cells (APCs). They can only induce a single humoral or cellular immune response, and the level of immune response induced by a single adjuvant is low, biased towards Th1 or Th2 type reactions, and has large toxicity and side effects.
[0004] Due to the human body CD4+T cells can differentiate into two subtypes, Th1 and Th2. Th1 is mainly characterized by inducing delayed hypersensitivity reactions, while Th2 is mainly characterized by inducing the production and secretion of specific antibodies. The two types of T cells restrict each other by secreting corresponding cytokines. Whether the body produces a Th1 or Th2 immune response to a vaccine will directly affect the protective effect of the vaccine on the body. The most ideal adjuvant, especially one derived from natural plants or microorganisms, should be able to cause the body to produce multiple types of immune responses (such as Th1 and Th2) against a certain specific source at the same time, and be safe, that is, after achieving the desired effect, it can also self-degrade in the body, and has no toxic side effects or potential carcinogenic or teratogenic effects, stable physical and chemical properties, not easy to decompose or denature, easy to produce, transport and store, and low production cost. In order to find a suitable vaccine adjuvant, the composite dual adjuvant strategy has become a research hotspot and focus of attention. For example, the patent with publication number CN107124869A discloses a non-toxic adjuvant preparation comprising a liposome composition containing monophosphoryl lipid A (MPLA) and quinoline saponin, wherein the liposome composition comprises i) a lipid bilayer comprising phospholipids, wherein the hydrocarbon chain has a melting temperature of ≥23°C in water, and ii) cholesterol at a molar percentage concentration greater than about 50% (mol / mol), preferably about 55% to about 71% (mol / mol), or more preferably about 55% (mol / mol). The main purpose of this patent is to maintain systemic safety and minimal side effects at the same time. The saponin in the vaccine adjuvant is selected from QS-7, QS-18 or QS-21. Among them, the saponins of the QS series are currently mainly from abroad, with high cost and poor hemolysis. At the same time, the above-mentioned saponins are synthetic saponins, and the side effects need to be considered, and there are still certain safety risks.
[0005] Therefore, there is an urgent need in the art to further improve vaccine adjuvants to overcome the defects and limitations of the prior art. Summary of the invention
[0006] The purpose of the present invention is to provide a natural microorganism and plant-derived composite dual adjuvant which can effectively induce humoral and cellular immunity, comprising monophosphoryl lipid A and ophiopogon saponin.
[0007] Furthermore, the ratio of the monophosphoryl lipid A to ophiopogon saponin is (3-8): (2-7).
[0008] A method for preparing a natural microorganism and plant-derived composite dual adjuvant that can efficiently induce humoral and cellular immunity, the specific preparation steps are as follows:
[0009] Step S1, completely dissolving monophosphoryl lipid A using one of Tween 80, castor oil, ethanol and propylene glycol;
[0010] Step S2, using one of Tween 85, hydrogenated castor oil, glycerin and Tween 20 to completely dissolve the ophiopogon japonicus saponin;
[0011] Step S3, the monophosphoryl lipid A solution and the ophiopogon japonicus saponin solution are fully and evenly mixed, and then dividedly packaged and sealed.
[0012] Furthermore, the order of step S1 and step S2 may be interchanged.
[0013] The solvent in step S1 and step S2 may also be other solvents.
[0014] Further, in step S3, the monophosphoryl lipid A solution and the ophiopogon japonicus saponin solution are mixed in the following order: slowly adding the monophosphoryl lipid A solution into the ophiopogon japonicus saponin solution and stirring during the adding process.
[0015] A composite dual adjuvant of natural microorganisms and plants that can effectively induce humoral and cellular immunity is used as a vaccine adjuvant.
[0016] A composite dual adjuvant of natural microorganisms and plants that can effectively induce humoral and cellular immunity and can be widely used as a vaccine adjuvant in various vaccines.
[0017] A composite dual adjuvant of natural microorganisms and plants that can effectively induce humoral and cellular immunity is used in the elderly and people with weakened immune function.
[0018] A natural microbial and plant-derived composite dual adjuvant that can effectively induce humoral and cellular immunity is applied to various stress populations. The stress population here refers to people who have self-stress reactions caused by factors such as physical trauma, physical and chemical stimulation, pathological and physiological stress, and social and cultural influences.
[0019] The composite double adjuvant of the present invention can be applied to a variety of vaccines and populations, especially vaccines and populations with low immune function due to stress such as trauma, and has strong applicability.
[0020] The principle of the present invention is:
[0021] In the application of vaccine adjuvants, the use of a single adjuvant has limited effect on improving the response intensity of antigens, the duration of immunity, immune tolerance, etc., and the single adjuvant stimulates a low level of immune response in the body, biases Th1 or Th2 type response, has weak APC presentation and delivery ability, and has large toxicity and side effects. The above characteristics of a single vaccine adjuvant limit its application development as another "immunogen" auxiliary antigen to achieve dual stimulation of antibody production; compared with a single adjuvant vaccine, a composite double adjuvant vaccine can induce a stronger immune response with a more balanced cellular and humoral immune response. Composite double adjuvant vaccines can not only reduce the amount of expensive antigens, enhance immune response, reduce the number of vaccinations, produce faster and more lasting immune responses, but also improve the effectiveness of vaccines against adverse responders. At the same time, it can play a synergistic role through different pathways to improve the immunogenicity of antigens, the intensity of immune response, regulate the type of immune response induced, improve immune memory, and reduce immune tolerance, thereby greatly enhancing the immune response.
[0022] In the early stage of the present invention, through large-scale screening research on the immune activity of various natural animal and plant immunostimulatory molecules, it was discovered for the first time that the poorly soluble intracellular immunostimulatory molecule Ophiopogon japonicus saponins with immunomodulatory function has good immune effects and can induce the body to produce an efficient Th2 humoral immune response; the extracellular immunostimulatory molecule MPLA can also efficiently induce the body to produce a Th1 cellular immune response. The present invention combines Ophiopogon japonicus saponins from natural plants with the TLR4 agonist molecule MPLA from natural microorganisms, and finds that the composite double adjuvant can not only play the advantages of a single adjuvant, but also is significantly better than a single adjuvant, and has a synergistic effect, thereby achieving the purpose of significantly enhancing the immune effect.
[0023] The beneficial effects of the present invention are:
[0024] (1) The composite dual adjuvant of the present invention has easy-to-obtain raw materials, simple preparation process, low cost and relatively stable;
[0025] (2) The present invention utilizes the complementary principles of pathways, response types and targets of two natural microorganisms and plant-derived adjuvants with a single immune response type to exert their synergistic advantages, which not only play a role in sustained release at the vaccination site and promoting antigen presentation, but also can produce efficient Th2 humoral and Th1 cellular immune responses, which can not only stimulate the body to produce efficient natural immune responses but also stimulate acquired immune responses;
[0026] (3) The composite dual adjuvant of the present invention is highly safe and can be applied to a variety of vaccines and populations, especially vaccines and populations with low immune function due to stress such as trauma;
[0027] (4) The composite dual adjuvant of the present invention is based on the internationally recognized extracellular immunostimulatory molecule MPLA that induces the body to produce a highly effective humoral immune response and the natural plant-derived intracellular immunostimulatory molecule Ophiopogon japonicus saponin that can induce the body to produce a cellular immune response, forming a composite dual adjuvant of natural microorganisms and plants. It has stable quality, good safety, and can simultaneously and efficiently induce the body to produce both humoral and cellular dual immune responses, and has strong practicality. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0029] Figure 1 This is a bar graph of the average serum specific antibody IgG of each group on the 7th day of Experiment 1.
[0030] Figure 2 This is a bar graph of the average serum specific antibody IgG1 of each group on the 7th day of Experiment 1.
[0031] Figure 3 This is a bar graph of the average serum specific antibody IgG2a of each group on the 7th day of Experiment 1.
[0032] Figure 4 This is a bar graph of the average serum specific antibody IgG2b of each group on the 7th day of Experiment 1.
[0033] Figure 5 This is a bar graph of the average serum specific antibody IgG of each group on the 14th day of Experiment 1.
[0034] Figure 6 This is a bar graph of the average serum specific antibody IgG1 of each group on the 14th day of Experiment 1.
[0035] Figure 7 This is a bar graph of the average serum specific antibody IgG2a of each group on the 14th day of Experiment 1.
[0036] Figure 8 This is a bar graph of the average serum specific antibody IgG2b of each group on the 14th day of Experiment 1.
[0037] Fig. 9 This is a bar graph of the average serum specific antibody IgG of each group on the 24th day of Experiment 1.
[0038] Fig.10This is a bar graph of the average serum specific antibody IgG1 of each group on the 24th day of Experiment 1.
[0039] Fig.11 This is a bar graph of the average serum specific antibody IgG2a of each group on the 24th day of Experiment 1.
[0040] Fig.12 This is a bar graph of the average serum specific antibody IgG2b of each group on the 24th day of Experiment 1.
[0041] Fig.13 This is a bar chart of the average serum specific antibody IgG of each group on the 14th day of Experiment 2.
[0042] Fig.14 This is a bar chart of the average serum specific antibody IgG of each group on the 21st day of Experiment 2.
[0043] Fig.15 This is a bar chart of the average serum specific antibody IgG of each group on the 21st day of Experiment 3.
[0044] Fig.16 This is a bar chart of the average serum specific antibody IgG of each group on the 35th day of Experiment 3.
[0045] Fig.17 This is a bar chart of the average serum specific antibody IgG of each group on the 14th day of Experiment 4.
[0046] Fig.18 This is a bar chart of the average serum specific antibody IgG of each group on the 35th day of Experiment 4. DETAILED DESCRIPTION
[0047] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0048] Example 1
[0049] A natural microorganism and plant-derived composite dual adjuvant capable of effectively inducing humoral and cellular immunity comprises MPLA and ophiopogon saponin, wherein the mass ratio of MPLA to ophiopogon saponin is 1:9.
[0050] Example 2
[0051] A natural microorganism and plant-derived composite dual adjuvant capable of effectively inducing humoral and cellular immunity comprises MPLA and ophiopogon saponin, wherein the mass ratio of MPLA to ophiopogon saponin is 2:8.
[0052] Example 3
[0053] A natural microorganism and plant-derived composite dual adjuvant capable of effectively inducing humoral and cellular immunity comprises MPLA and ophiopogon saponin, wherein the mass ratio of MPLA to ophiopogon saponin is 3:7.
[0054] Example 4
[0055] A natural microorganism and plant-derived composite dual adjuvant capable of effectively inducing humoral and cellular immunity comprises MPLA and ophiopogon saponin, wherein the mass ratio of MPLA to ophiopogon saponin is 4:6.
[0056] Example 5
[0057] A natural microorganism and plant-derived composite dual adjuvant capable of effectively inducing humoral and cellular immunity comprises MPLA and ophiopogon saponin, wherein the mass ratio of MPLA to ophiopogon saponin is 5:5.
[0058] Example 6
[0059] A natural microorganism and plant-derived composite dual adjuvant capable of effectively inducing humoral and cellular immunity comprises MPLA and ophiopogon saponin, wherein the mass ratio of MPLA to ophiopogon saponin is 6:4.
[0060] Example 7
[0061] A natural microorganism and plant-derived composite dual adjuvant capable of effectively inducing humoral and cellular immunity comprises MPLA and ophiopogon saponin, wherein the mass ratio of MPLA to ophiopogon saponin is 7:3.
[0062] Example 8
[0063] A natural microorganism and plant-derived composite dual adjuvant capable of effectively inducing humoral and cellular immunity comprises MPLA and ophiopogon saponin, wherein the mass ratio of MPLA to ophiopogon saponin is 8:2.
[0064] Example 9
[0065] A natural microorganism and plant-derived composite dual adjuvant capable of effectively inducing humoral and cellular immunity comprises MPLA and ophiopogon saponin, wherein the mass ratio of MPLA to ophiopogon saponin is 9:1.
[0066] Example 10
[0067] A method for preparing a natural microorganism and plant-derived composite dual adjuvant that can efficiently induce humoral and cellular immunity, characterized in that the specific preparation steps are as follows:
[0068] Step S1, using one of the solvents such as Tween 80, castor oil and ethanol to completely dissolve the monophosphoryl lipid A;
[0069] Step S2, using one of the solvents selected from Tween 85, hydrogenated castor oil and glycerin to completely dissolve the ophiopogon japonicus saponin;
[0070] Step S3, the monophosphoryl lipid A solution and the ophiopogon japonicus saponin solution are fully and evenly mixed, and then sealed and packaged.
[0071] The order of the above step S1 and step S2 can be interchanged. In the actual preparation process, step S1 and step S2 are independent processes and will not affect each other.
[0072] In step S3, the monophosphoryl lipid A solution and the ophiopogon japonicus saponin solution are mixed in the following order: slowly adding the monophosphoryl lipid A solution into the ophiopogon japonicus saponin solution and stirring during the adding process.
[0073] Embodiments 1 to 9 were prepared respectively by the method of Embodiment 10 to obtain finished products.
[0074] Experiment and conclusion
[0075] Experiment 1: Detection of the immune response of normal mice after HI with different ratios of composite double adjuvants combined with recombinant subunit vaccine of Staphylococcus aureus (MRSA)
[0076] 110 BALB / c mice in SPF environment were randomly divided into 11 groups, 10 mice in each group, numbered 1 to 11, and injected intramuscularly with natural microorganisms and plant-derived composite double adjuvants combined with recombinant Staphylococcus aureus (HI antigen) vaccine containing dual-stimulation immune response, 100ul per mouse. Among them, in groups 1 and 11, the ratio of monophosphoryl lipid A to Ophiopogon japonicus saponin OPD was 0:10 and 10:0 respectively (i.e., single adjuvant vaccine in groups 1 and 11). The above composite double adjuvant vaccines were injected bilaterally into the muscles of Blab / c mice, with 30μg HI antigen per mouse and a total dose of 30μg of composite double adjuvant. After three intramuscular injections on days 0, 7, and 14, the serum specific IgG antibody titers were detected on days 7, 14, and 24. The specific composition of the composite double adjuvants in each group is shown in Table 1 below; the average serum specific antibody in each experimental group is as follows Figure 1-Figure 12 shown.
[0077] Table 1 Comparison of specific ratios of composite adjuvants of composite immunostimulatory molecules injected in each group
[0078]
[0079]
[0080] pass Figure 1-Figure 12 It can be seen that compared with the experimental group using a single adjuvant, the experimental group using a composite double adjuvant can simultaneously and efficiently induce the body to produce a dual humoral and cellular immune response. In actual use, the specific ratio of MPLA and ophiopogonin can be adjusted according to the specific situation. If you need to increase the level of IgG1, IgG2a or IgG2b in the body, you can refer to the results of this experiment. If you need to increase the level of IgG2a in the body, the ratio of MPLA to ophiopogonin can be preferably 3:7; if you need to increase the level of IgG1 in the body, the ratio of MPLA to ophiopogonin can be preferably 4:6; if you need to increase the level of IgG2b in the body, the ratio of MPLA to ophiopogonin can be preferably 8:2.
[0081] Experiment 2: Detection of the effect of the composite double adjuvant combined with Staphylococcus aureus recombinant protein HI antigen on the immune response enhancement of normal mice
[0082] Fifty BALB / c mice raised in an SPF environment were randomly divided into 5 groups, with 10 mice in each group. The groups were HI pure antigen group, OPD adjuvant group, MPLA adjuvant group, Double adjvuant adjuvant group and Alum adjuvant group.
[0083] Among them, no adjuvant was added to the HI pure antigen group;
[0084] The OPD adjuvant group consisted of HI pure antigen + OPD single adjuvant with ophiopogon japonicus saponin;
[0085] The MPLA adjuvant group consisted of HI pure antigen + MPLA single adjuvant;
[0086] Double adjvuant adjuvant group is HI pure antigen + composite double adjuvant (Ophiopogon japonicus saponin OPD and MPLA mixed double adjuvant);
[0087] The Alum adjuvant group consisted of HI pure antigen + Alum single adjuvant.
[0088] The above-mentioned adjuvants were combined with HI antigens and injected into the thigh muscles of Blab / c mice. Each mouse was injected with 100ul intramuscularly. In each of the above groups, the HI antigen added with adjuvant was 30μg, and the total amount of adjuvant was 50μg. After three intramuscular injections on days 0, 7, and 14, serum-specific IgG antibodies were tested on days 14 and 28 after immunization. The average serum-specific antibodies in each experimental group are as follows: Figure 13-Figure 14 shown.
[0089] pass Fig.13 and Fig.14It can be seen that among the groups with added antigens, the immune responses of the groups with added adjuvants were stronger than those of the experimental groups without added adjuvants; and among the groups with added adjuvants, the immune response of the experimental group with added natural microorganisms and plant-derived composite dual adjuvants for dual-stimulation immune response of the present invention was the strongest.
[0090] Experiment 3: Effect of the composite double adjuvant combined with Staphylococcus aureus recombinant protein HI antigen on the immune response enhancement of traumatic stress mice
[0091] 60 BALB / c mice raised in an SPF environment were selected and subjected to traumatic stress treatment. The specific process was as follows: After the mice were anesthetized and depilated with depilatory cream, wounds of the same size (1×1 cm) were cut on the back skin of each mouse with scissors for trauma treatment. Then they were randomly divided into 6 groups, with 10 mice in each group, namely PBS control group, HI pure antigen group, MPLA adjuvant group, OPD adjuvant group, Double adjvuant adjuvant group and Alum adjuvant group.
[0092] Among them, the PBS control group was pure PBS buffer without antigen and adjuvant;
[0093] No adjuvant was added to the HI pure antigen group;
[0094] The MPLA adjuvant group consisted of HI pure antigen + MPLA single adjuvant;
[0095] The OPD adjuvant group consisted of HI pure antigen + OPD single adjuvant with ophiopogon japonicus saponin;
[0096] Double adjvuant adjuvant group is HI pure antigen + composite double adjuvant (Ophiopogon japonicus saponin OPD and MPLA mixed double adjuvant);
[0097] The Alum adjuvant group consisted of HI pure antigen + Alum single adjuvant.
[0098] The PBS control group mice were injected with 100ul 0.1mmol / L PBS buffer, and the other groups of adjuvants combined with HI antigen were injected bilaterally into the thigh muscles of Blab / c mice, and the intramuscular immunization volume of each mouse was 100ul. In the above groups, the HI antigen of each group with adjuvant added was 30μg, and the total amount of adjuvant was 50μg. After three intramuscular injections on days 0, 7, and 14, serum-specific IgG antibodies were tested for each group on days 21 and 35. The average serum-specific antibody situation in each experimental group is as follows: Figure 15-16 shown.
[0099] pass Figure 15-16It can be seen that the antibody titer of the PBS group without adding antigen is the lowest; among the groups with added antigen, the immune response of the groups with added adjuvant is stronger than that of the experimental group without adding adjuvant; and among the groups with added adjuvant, the immune response of the experimental group with added natural microorganism and plant-derived composite double adjuvant for dual stimulation of immune response of the present invention is the strongest.
[0100] Experiment 4: Detection of the effect of compound double adjuvant combined with standard model OVA antigen on the immune response enhancement of normal mice
[0101] A total of 60 BALB / c mice raised in an SPF environment were randomly divided into 6 groups, with 10 mice in each group. The groups were PBS control group, OVA pure protein antigen group, OPD+OVA group, MPLA+OVA group, Double adjvuant+OVA group and MF59 adjuvant+OVA group.
[0102] Among them, the PBS control group was pure LPBS buffer without antigen and adjuvant;
[0103] The OVA pure protein antigen group was pure antigen without adjuvant;
[0104] The OPD+OVA group was OVA pure protein antigen + OPD single adjuvant with ophiopogon japonicus saponin;
[0105] The MPLA+OVA group consisted of OVA pure protein antigen + MPLA single adjuvant;
[0106] Double adjvuant+OVA group was OVA pure protein antigen + composite double adjuvant (Ophiopogon japonicus saponin OPD and MPLA mixed double adjuvant);
[0107] The MF59+OVA group was OVA pure protein antigen + MF59 single adjuvant.
[0108] The PBS control group was injected with 100ul of 0.1mmol / L PBS buffer, and the other groups of adjuvants combined with OVA antigen were injected bilaterally into the thigh muscles of Blab / c mice, with a total injection of 100ul per mouse. The OVA antigen in each group with adjuvant added was 20μg, and the total adjuvant was 50μg. After three intramuscular injections on days 0, 14, and 28, serum-specific IgG antibodies were tested for each group on days 14 and 35 after immunization. The average serum-specific antibody situation in each experimental group is as follows: Figure 17-Figure 18 shown.
[0109] pass Figure 17-Figure 18It can be seen that the immune antibody level of the PBS group without adding antigen is the lowest; among the groups with added antigen, the immune response of the groups with added adjuvant is stronger than that of the experimental group without adding adjuvant; and among the groups with added adjuvant, the immune response of the experimental group with added natural microorganism and plant-derived composite double adjuvant for dual stimulation of immune response of the present invention is the strongest.
[0110] Based on the above experiments 1 to 4, it can be seen that the natural microorganism and plant-derived composite dual adjuvant of the present invention, which can efficiently induce dual immune responses of humoral and cellular immunity, can significantly enhance the antibody level of specific IgG in mouse serum and enhance the immune response of mice compared with other single adjuvants.
[0111] The specific implementation methods described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific implementation method of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the scope of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for preparing a natural microorganism and plant-derived composite dual adjuvant that can efficiently induce humoral and cellular immunity, characterized in that: The specific preparation steps are as follows: Step S1, completely dissolving monophosphoryl lipid A using one of Tween 80, castor oil, ethanol and propylene glycol; Step S2, using one of Tween 85, hydrogenated castor oil, glycerin and Tween 20 to completely dissolve the ophiopogon japonicus saponin; Step S3, fully and evenly mixing the monophosphoryl lipid A solution and the ophiopogon japonicus saponin solution, and sealing the mixture in divided packages; In step S3, the mass ratio of monophosphoryl lipid A to ophiopogon japonicus saponin is (3-8): (2-7).
2. The method for preparing a natural microorganism and plant-derived composite dual adjuvant capable of efficiently inducing humoral and cellular immunity according to claim 1, characterized in that: In step S3, the monophosphoryl lipid A solution and the ophiopogon japonicus saponin solution are mixed in the following order: slowly adding the monophosphoryl lipid A solution into the ophiopogon japonicus saponin solution and stirring during the adding process.
3. A method for preparing a natural microorganism and plant-derived composite dual adjuvant capable of efficiently inducing humoral and cellular immunity as claimed in claim 1 or 2, wherein the composite dual adjuvant capable of efficiently inducing humoral and cellular immunity and comprising: The invention comprises monophosphoryl lipid A and ophiopogon japonicus saponin, and the mass ratio of monophosphoryl lipid A to ophiopogon japonicus saponin is (3-8): (2-7).
4. A use of the natural microorganism and plant-derived composite double adjuvant capable of efficiently inducing humoral and cellular immunity prepared by the method for preparing the natural microorganism and plant-derived composite double adjuvant capable of efficiently inducing humoral and cellular immunity as claimed in claim 3 in the preparation of vaccine adjuvants, characterized in that: The composite double adjuvant includes monophosphoryl lipid A (MPLA) and ophiopogon japonicus saponin, and the mass ratio of monophosphoryl lipid A to ophiopogon japonicus saponin is (3-8): (2-7).
Citation Information
Patent Citations
Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin
CN107124869A
Novel and universal type matrix vaccine adjuvant, and preparation method and application thereof
CN105169386A
Ophiopogonin D and application of nanoemulsion thereof in preparation of vaccine adjuvant
CN108853493A
Composite water-soluble animal vaccine adjuvant, vaccine and preparation method of vaccine
CN113082202A
